Articles related to MENTAL HEALTH

To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases due to challenges at the blood-brain barrier. James Bibb, Ph.D., and colleagues seek to change that notion with their brain-permeable compound, 25-106.

A follow-up to the discussion we recently presented, this article asks doctors to look beyond the physical health of the patient to recognize and potentially treat muscle dysmorphia, the notion in which an individual is preoccupied with the idea that his or her body build is too small or insufficiently muscular.

The authors concluded that, after reviewing the 13-year-study, “switching to LAIs during the first 3 years of treatment improved antipsychotic adherence, decreased relapses, and reduced long-term mortality.” With few studies available comparing the long-term effectiveness between patients who switched to LAIs and those who remained on oral antipsychotics (OAPs), they hope the evidence presented supports the benefits of early LAI treatment in schizophrenia.

A video and transcript of a conversation between Harrison “Skip” Pope Jr., MD, MPH, of Harvard Medical School, and Katharine Phillips, MD, of New York-Presbyterian/Weill Cornell Medical Center, who discuss symptoms, treatments, and social propagation of “muscle dysmorphia”: a preoccupation with the belief that one’s body isn’t large or muscular enough.

Looking for some stimulating summer reading? From addiction to therapists to the psychopathy in charismatic leaders, these are books that can improve your understanding of yourself and others in your practice.

In this cross-sectional study of 586 probands and 698 first-degree relatives, cannabis use disorder and bipolar disorder II in probands were associated with an independent increase in risk of cannabis use disorder in relatives; bipolar disorder I and major depressive disorder in probands were not significantly associated with cannabis use disorder in relatives. The risk of cannabis use disorder was highest among relatives with both familial and individual history of bipolar disorder II.